Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Onconova Thera Form 4 January 28, 2010	•										
FORM 4	1									APPROV	AL
	STATES	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					N OMB Number:		-0287		
Check this be if no longer subject to Section 16. Form 4 or Form 5 obligations may continue <i>See</i> Instruction 1(b).	STATEN Filed pur Section 17(rsuant to S (a) of the 3	IENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES suant to Section 16(a) of the Securities Exchange Act of 1934, a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						Estimated burden ho response.	ours per	
(Print or Type Resp	onses)										
1. Name and Address of Reporting Person <u>*</u> MCKEARN THOMAS J			2. Issuer Name and Ticker or Trading Symbol Onconova Therapeutics, Inc. [ONTX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O ONCONOVA THERAPEUTICS, INC., 375 PHEASANT RUN			3. Date of Earliest Transaction (Month/Day/Year) 01/26/2016				Director 10% Owner X Officer (give title Other (specify below) below) President, R&D				
NEWTOWN, F	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year) PA 18940					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 					
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securi	ities A	cquired, Disposed	of, or Benefici	ally Own	ed
	ransaction Date onth/Day/Year)	2A. Deem Execution any (Month/D.	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Natur Indirect Benefic Owners (Instr. 4	al hip
Reminder: Report of	on a separate line	e for each cl	ass of sec	urities benef	ficially ow	ned dir	ectly o	r indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	TransactiorDerivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code N	' (A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to purchase)	\$ 0.65	01/26/2016		А	71,029	<u>(1)</u>	01/26/2026	common stock	71,029	

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
reporting o when Auno / Martess	Director	10% Owner	Officer	Other			
MCKEARN THOMAS J C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN NEWTOWN, PA 18940			President, R&D				
Signatures							
/s/ Ajay Bansal as	2/2016						

attorney-in-fact

01/28/2016

Date

Signature of Reporting Person **Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). **

(1) These options vest, 25% on January 26, 2016 and 75% on December 31, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.